NES ZIONA, Israel–(BUSINESS
WIRE)–OrSense Ltd., developer of monitors for non-invasive measurements of
various blood parameters, announced today that two oral presentations on the
clinical value of its NBM 200 non-invasive hemoglobin (Hb) monitor for maternal
health and anemia monitoring prior, during and post delivery of pregnant women
will be presented at the 4th Asia Pacific Congress on Controversies in Obstetrics
Gynecology and Infertility (COGI), in Bangkok, Thailand, to be held on
November 24-27, 2011.
The following oral presentations will introduce data
obtained with OrSense’s device for the non-invasive monitoring of Hb levels:
Anemia during pregnancy: a controlled risk of maternal
mortality. Professor Gian Carlo di Renzo, Chairman of the Department of
Obstetrics and Gynecology and Centre for Perinatal and Reproductive Medicine, Santa Maria della
Misericordia University
Hospital, Perugia, Italy.
Maternal mortality in the world: some good news. Dr. Luis
Cabero Roura, Head of the Department of Obstetrics and Gynecology of Hospital
Materno-infantil Valle Hebron, Barcelona,
Spain.
Professor Moshe Hod, Director, Division of Maternal Fetal
Medicine, Helen Schneider Hospital for Woman, Rabin Medical Center, Israel and
Co-Chairperson of COGI, said, “OrSense’s device has proven its accuracy
and ease of use in determining hemoglobin levels non-invasively. I believe that
this device offers a much-needed viable solution for non-invasive anemia
screening and management through pregnancy and assists in reducing maternal
morbidity and mortality in the peripartum period.”
Over one billion people suffer from iron deficiency anemia
worldwide. During pregnancy the need for iron increases and exposes the mother
to a higher risk of anemia. Anemia is a prime reason for maternal mortality and
acts as a predisposition for low neonate birth weight. In addition, severe
anemia may aggravate the negative effect of postpartum hemorrhage, and endanger
the mother. It is estimated that 40% of maternal deaths are caused directly or
indirectly by anemia.
Reducing maternal mortality is one of the key global healthcare
objectives. Close to 350,000 women die each year due to lack of proper
diagnosis and treatment and several millions are affected. The inability to
identify and treat anemia and hemorrhage in the developing world due to lack of
infrastructure and personnel is a key limitation in the UN and WHO efforts to
reduce maternal mortality.
OrSense has developed and commercialized a non-invasive,
portable monitoring system for measuring spot and continuous hemoglobin and
other blood parameters. NBM 200 offers, for the first time an accurate, safe,
fast, easy to operate and affordable solution that would allow for anemia
screening and monitoring. Being non-invasive, it eliminates the need for finger
prick and biochemistry based blood test, prevents infection risks and
eliminates the need for handling bio-hazardous material. The continuous
non-invasive hemoglobin functionality can serve for early detection of post
partum hemorrhage and improved blood management post delivery. It has the
potential of improving maternal health by offering online needed information
and eliminating safety risks while reducing cost of care. The device is based
on OrSense’s proprietary Occlusion Spectroscopy technology, which uses a
non-invasive optical measurement platform combined with a ring-shaped pneumatic
probe that fits on the finger.
About OrSense
OrSense is a medical device company developing and marketing non-invasive
monitoring systems for measurements of hemoglobin, oxygen saturation, glucose
and other blood parameters. OrSenses CE approved non-invasive hemoglobin
monitor is available in 40 countries worldwide, and has been successfully
installed in multiple environments including hospitals, physician offices,
blood donation facilities, as well as used for various applications including
public screening, women’s health and homecare. In addition, the Company’s FDA
cleared NBM 200MP is a non-invasive blood oximetry monitor for use in
hospitals. OrSense’s products are based on its proprietary Occlusion
Spectroscopy technology, which overcomes key obstacles that hinder the
performance of competing approaches. The Company’s CE approved glucose monitor
was tested on over 450 diabetic subjects, showing performance similar to those
of invasive glucose sensors. Investors in the Company include Israel Health
Care Ventures and STAR Ventures. For additional information, please visit
OrSenses corporate website at www.orsense.com.
